← All trials
NCT05742984
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2023
- Primary completion
- Mar 24, 2023
- Completion date
- Sep 28, 2023
- First posted
- Feb 24, 2023
- Last posted
- Sep 6, 2023
- Enrollment
- 72
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cinclus Pharma AGLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.